Pacira Pharmaceuticals Inc. Oct. 31 announced that the Food and Drug Administration has approved Exparel (bupivacaine liposome injectable suspension) 1.3 percent for administration into the surgical site to produce postsurgical analgesia.
Exparel is an innovative product that combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period, the Parsippany, N.J.-based company said. By utilizing the DepoFoam platform, a single dose of Exparel delivers bupivacaine for an extended period of time, providing analgesia with reduced opioid requirements for up to 72 hours.
Pacira said Exparel is the first and only multivesicular liposome local anesthetic ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.